Mycibact Iv 500 mg Tablet
PDF Leaflet Revision Date: 15 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of community acquired pneumonia requiring intravenous therapy.
Dosage (summary)
500 mg IV daily for at least 2 days, followed by 500 mg orally for 7-10 days.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Use only if clearly indicated; may pass into breast milk.
Key Drug Interactions
- Digoxin
- Warfarin
- Ergot derivatives
Contraindications
- Hypersensitivity to azithromycin
- Hepatic disease
Common side effects
- Diarrhoea
- Nausea
- Dizziness
- Headache
Counselling Points
- Monitor for allergic reactions
- Avoid use with ergot derivatives
- Report any signs of liver dysfunction
Serious warnings
- Risk of QT prolongation
- Hepatotoxicity
- Severe allergic reactions
Important Disclaimer
The Mycibact Iv 500 mg Tablet professional information leaflet below is the property of Austell Pharmaceutical and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
